Company Announcement / Press release Archives - Page 17 of 18

Xspray Pharma’s nomination committee for the annual general meeting 2019

STOCKHOLM, SWEDEN – November 23, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) publishes the nomination committee’s composition for the annual general meeting in 2019. The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting on 14 May 2018, consists of: Gillis Cullin, appointed by Östersjöstiftelsen Anders Bladh, appointed by Ribbskottet […]

Xspray Pharma prepares for listing on main list

STOCKHOLM, SWEDEN – October 25, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) today announced the decision of the company's board of directors that Xspray will apply for listing of the company's share on Nasdaq Stockholm's main list. The list change is expected to take place within 12 months and is made to improve the prerequisites for a […]

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), reg. no. 556649-3671 are hereby summoned to attend the extraordinary general meeting ("EGM") on Wednesday 28 November 2018 at 10.00 a.m. CET at Advokatfirman Cederquist’s premises on Hovslagargatan 3 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept by […]

Xspray Pharma’s HyNap-Dasa Shows Formal Bioequivalence

STOCKHOLM, SWEDEN – October 10, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) can today present data confirming formal bioequivalence for the company’s lead product candidate, HyNap-Dasa, compared to Sprycel® (dasatinib). ”It has taken us three years of work to come to these encouraging results and the excitement in the company is clearly present today. We […]

Ribbskottet AB increases its stake in Xspray Pharma

STOCKHOLM – September 24, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) (“Xspray”) has received information that Ribbskottet AB has purchased a total of 223,000 shares in the company from Recipharm Venture Fund AB. The transfer took place outside the stock exchange. Ribbskottet’s holding in Xspray now amounts to 10 percent of the number of shares […]

Xspray Pharma announces positive clinical data for its lead product candidate HyNap-Dasa

STOCKHOLM – September 9, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) today announces positive data from a clinical bioequivalence study with the company’s lead product candidate HyNap-Dasa. The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sprycel®. The data will be instrumental in the design […]

Xspray Pharma and NerPharMa deliver clinical trial material to HyNap-Dasa study

Today, Xspray Pharma reported that the first clinical trial material from NerPharMa S.r.l., Xspray’s strategic pharmaceutical manufacturing partner in Milan, has been delivered to the HyNap-Dasa clinical trial, the results of which are expected in Q3 2018. HyNap-Dasa is one of three product candidates that Xspray currently has in development. The company’s goal is to […]

Xspray Pharma gets go-ahead from the Swedish MPA for clinical study

Xspray Pharma has obtained approval from the Swedish Medical Products Agency (MPA) to carry out a previously announced clinical study of the formulation of the company’s product candidate HyNap-Dasa. The study is part of Xspray’s clinical program and will be completed during the third quarter. The objective is to confirm the bioequivalence of the optimized […]

Xspray Pharma Chariman divests 4,000 shares to cover Danish capital gains tax on unrealised gains on Xspray Pharma shares

Xspray Pharma’s Chairman, Michael Wolff Jensen’s private, fully owned holding company MWJ Partners ApS has sold 4,000 shares in Xspray Pharma. The proceeds cover incurred Danish capital gains tax, which is charged on unrealized capital gains on MWJ Partners’ holding of shares in Xspray Pharma. After the transaction, Michael Wolff Jensen holds 31,864 shares and […]

Notice of annual general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), reg. no. 556649-3671 are hereby summoned to attend the annual general meeting ("AGM") on Monday, 14 May, 2018, at 11.00 a.m. CET at IVA Konferenscenter’s premises on Grev Turegatan 16 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept […]